Elizabeth Pomfret
Concepts (512)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 128 | 2025 | 871 | 17.550 |
Why?
| | Living Donors | 76 | 2025 | 295 | 13.700 |
Why?
| | Tissue and Organ Procurement | 39 | 2025 | 321 | 8.010 |
Why?
| | Tissue Donors | 18 | 2025 | 425 | 3.460 |
Why?
| | Hepatectomy | 25 | 2025 | 251 | 3.370 |
Why?
| | Donor Selection | 16 | 2024 | 77 | 3.200 |
Why?
| | Kidney Transplantation | 16 | 2025 | 708 | 2.580 |
Why?
| | End Stage Liver Disease | 12 | 2023 | 82 | 2.400 |
Why?
| | Organ Transplantation | 16 | 2025 | 250 | 2.300 |
Why?
| | Perfusion | 8 | 2025 | 213 | 2.060 |
Why?
| | Liver | 42 | 2023 | 1943 | 1.990 |
Why?
| | Patient Selection | 14 | 2023 | 696 | 1.960 |
Why?
| | Carcinoma, Hepatocellular | 9 | 2023 | 362 | 1.900 |
Why?
| | Liver Neoplasms | 10 | 2023 | 786 | 1.580 |
Why?
| | Postoperative Complications | 27 | 2024 | 2654 | 1.530 |
Why?
| | Resource Allocation | 5 | 2025 | 52 | 1.480 |
Why?
| | Waiting Lists | 16 | 2025 | 266 | 1.380 |
Why?
| | Liver Cirrhosis | 9 | 2020 | 316 | 1.340 |
Why?
| | Tissue and Organ Harvesting | 10 | 2024 | 70 | 1.330 |
Why?
| | Graft Survival | 19 | 2025 | 535 | 1.280 |
Why?
| | Humans | 182 | 2025 | 137585 | 1.110 |
Why?
| | Laparoscopy | 3 | 2023 | 466 | 0.980 |
Why?
| | Informed Consent | 3 | 2024 | 175 | 0.970 |
Why?
| | United States | 43 | 2025 | 14841 | 0.960 |
Why?
| | Organ Preservation | 6 | 2025 | 102 | 0.960 |
Why?
| | Fatty Liver | 6 | 2023 | 243 | 0.950 |
Why?
| | Lung Transplantation | 3 | 2025 | 313 | 0.930 |
Why?
| | Hepatitis C, Chronic | 5 | 2022 | 164 | 0.930 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 51 | 0.910 |
Why?
| | Liver Diseases | 5 | 2023 | 315 | 0.850 |
Why?
| | Immunotoxins | 4 | 2025 | 55 | 0.800 |
Why?
| | Consensus Development Conferences as Topic | 2 | 2020 | 31 | 0.780 |
Why?
| | Consensus | 9 | 2024 | 683 | 0.770 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 130 | 0.750 |
Why?
| | Graft Rejection | 13 | 2020 | 624 | 0.740 |
Why?
| | Surgeons | 3 | 2025 | 297 | 0.720 |
Why?
| | Liver Failure | 7 | 2016 | 94 | 0.700 |
Why?
| | Adult | 75 | 2025 | 37929 | 0.690 |
Why?
| | Middle Aged | 69 | 2025 | 33479 | 0.640 |
Why?
| | Frailty | 1 | 2023 | 170 | 0.640 |
Why?
| | Pain, Postoperative | 3 | 2016 | 265 | 0.630 |
Why?
| | Portal Vein | 4 | 2017 | 120 | 0.610 |
Why?
| | Diphtheria Toxin | 4 | 2025 | 66 | 0.610 |
Why?
| | Male | 87 | 2025 | 67762 | 0.600 |
Why?
| | Female | 86 | 2025 | 73304 | 0.600 |
Why?
| | Treatment Outcome | 34 | 2025 | 10811 | 0.560 |
Why?
| | Immunosuppressive Agents | 6 | 2018 | 890 | 0.540 |
Why?
| | Transplant Recipients | 7 | 2025 | 184 | 0.540 |
Why?
| | Hepatic Veins | 5 | 2016 | 33 | 0.520 |
Why?
| | Survival Rate | 14 | 2025 | 1972 | 0.520 |
Why?
| | Kidney Failure, Chronic | 4 | 2025 | 570 | 0.520 |
Why?
| | Thrombelastography | 6 | 2023 | 154 | 0.520 |
Why?
| | Healthcare Disparities | 6 | 2025 | 654 | 0.510 |
Why?
| | Antiviral Agents | 4 | 2022 | 744 | 0.490 |
Why?
| | Blood Coagulation Disorders | 4 | 2022 | 173 | 0.480 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2017 | 26 | 0.480 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 279 | 0.470 |
Why?
| | Venous Thrombosis | 1 | 2017 | 190 | 0.470 |
Why?
| | Transplantation, Homologous | 8 | 2020 | 416 | 0.470 |
Why?
| | Biopsy | 9 | 2020 | 1129 | 0.460 |
Why?
| | Societies, Medical | 4 | 2024 | 820 | 0.450 |
Why?
| | Retrospective Studies | 31 | 2025 | 15657 | 0.440 |
Why?
| | Sirolimus | 1 | 2016 | 276 | 0.430 |
Why?
| | Interleukin-2 | 4 | 2024 | 455 | 0.420 |
Why?
| | Tissue Plasminogen Activator | 4 | 2023 | 224 | 0.420 |
Why?
| | Biliary Tract Diseases | 2 | 2010 | 39 | 0.410 |
Why?
| | Kidney | 6 | 2023 | 1468 | 0.410 |
Why?
| | Hepacivirus | 7 | 2022 | 261 | 0.390 |
Why?
| | Periodicals as Topic | 1 | 2015 | 211 | 0.390 |
Why?
| | Registries | 6 | 2025 | 2035 | 0.390 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2023 | 1079 | 0.380 |
Why?
| | Tomography, X-Ray Computed | 9 | 2017 | 2691 | 0.380 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 110 | 0.370 |
Why?
| | Risk Factors | 17 | 2025 | 10388 | 0.360 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2023 | 43 | 0.360 |
Why?
| | Hepatitis C | 5 | 2022 | 271 | 0.360 |
Why?
| | Follow-Up Studies | 12 | 2025 | 5131 | 0.350 |
Why?
| | Liver Regeneration | 4 | 2003 | 46 | 0.340 |
Why?
| | Allografts | 3 | 2023 | 146 | 0.340 |
Why?
| | Prognosis | 10 | 2025 | 4030 | 0.330 |
Why?
| | Resuscitation | 2 | 2024 | 251 | 0.330 |
Why?
| | Patient Safety | 1 | 2012 | 314 | 0.310 |
Why?
| | Directed Tissue Donation | 1 | 2008 | 4 | 0.300 |
Why?
| | Biliary Tract | 1 | 2008 | 17 | 0.300 |
Why?
| | Blood Coagulation | 5 | 2023 | 255 | 0.300 |
Why?
| | Bioethical Issues | 1 | 2008 | 8 | 0.300 |
Why?
| | Terminology as Topic | 3 | 2024 | 216 | 0.300 |
Why?
| | Vascular Surgical Procedures | 1 | 2011 | 303 | 0.290 |
Why?
| | Time Factors | 16 | 2025 | 6828 | 0.290 |
Why?
| | Interpersonal Relations | 1 | 2011 | 397 | 0.290 |
Why?
| | Adolescent | 23 | 2024 | 21513 | 0.280 |
Why?
| | Quality of Life | 7 | 2020 | 2892 | 0.280 |
Why?
| | Severity of Illness Index | 8 | 2023 | 2828 | 0.280 |
Why?
| | Software | 2 | 2012 | 665 | 0.280 |
Why?
| | Transplants | 2 | 2022 | 36 | 0.270 |
Why?
| | Aged | 31 | 2025 | 23961 | 0.270 |
Why?
| | Tacrolimus | 3 | 2020 | 199 | 0.260 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2006 | 16 | 0.260 |
Why?
| | Fibrinolysis | 3 | 2023 | 146 | 0.260 |
Why?
| | Young Adult | 12 | 2024 | 13209 | 0.260 |
Why?
| | Transplantation Immunology | 1 | 2006 | 34 | 0.250 |
Why?
| | Insurance, Life | 1 | 2005 | 2 | 0.240 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2129 | 0.240 |
Why?
| | International Cooperation | 2 | 2016 | 198 | 0.230 |
Why?
| | CD47 Antigen | 1 | 2025 | 38 | 0.230 |
Why?
| | Flank Pain | 1 | 2024 | 10 | 0.230 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 26 | 0.230 |
Why?
| | Renal Nutcracker Syndrome | 1 | 2024 | 9 | 0.230 |
Why?
| | Intestines | 2 | 2007 | 357 | 0.220 |
Why?
| | Health Care Rationing | 3 | 2013 | 59 | 0.220 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1587 | 0.220 |
Why?
| | Decision Making | 1 | 2011 | 900 | 0.220 |
Why?
| | Critical Care | 4 | 2024 | 601 | 0.220 |
Why?
| | Solitary Kidney | 1 | 2023 | 5 | 0.210 |
Why?
| | Skin Neoplasms | 2 | 2023 | 855 | 0.210 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 548 | 0.210 |
Why?
| | Transplantation, Autologous | 1 | 2024 | 238 | 0.210 |
Why?
| | Sezary Syndrome | 1 | 2023 | 44 | 0.210 |
Why?
| | Risk Assessment | 9 | 2022 | 3457 | 0.200 |
Why?
| | Mycosis Fungoides | 1 | 2023 | 61 | 0.200 |
Why?
| | Body Mass Index | 2 | 2024 | 2389 | 0.200 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2011 | 1329 | 0.200 |
Why?
| | Congresses as Topic | 1 | 2024 | 233 | 0.200 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 32 | 0.200 |
Why?
| | Length of Stay | 3 | 2023 | 1215 | 0.200 |
Why?
| | Body Temperature | 1 | 2023 | 222 | 0.200 |
Why?
| | Operative Time | 1 | 2023 | 145 | 0.190 |
Why?
| | Death | 3 | 2023 | 119 | 0.190 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2023 | 80 | 0.190 |
Why?
| | Thrombosis | 3 | 2022 | 371 | 0.190 |
Why?
| | Bile Ducts | 2 | 2022 | 71 | 0.190 |
Why?
| | Massachusetts | 2 | 2012 | 172 | 0.180 |
Why?
| | Sodium | 1 | 2022 | 217 | 0.180 |
Why?
| | Case-Control Studies | 5 | 2023 | 3556 | 0.180 |
Why?
| | Antibiotic Prophylaxis | 2 | 2020 | 119 | 0.180 |
Why?
| | Evidence-Based Medicine | 3 | 2016 | 740 | 0.180 |
Why?
| | Cause of Death | 3 | 2025 | 434 | 0.180 |
Why?
| | Sex Factors | 3 | 2024 | 2071 | 0.170 |
Why?
| | Recurrence | 10 | 2011 | 1060 | 0.170 |
Why?
| | Prothrombin Time | 1 | 2000 | 35 | 0.170 |
Why?
| | Predictive Value of Tests | 5 | 2020 | 2031 | 0.170 |
Why?
| | Physicians | 2 | 2010 | 910 | 0.170 |
Why?
| | Cholangitis, Sclerosing | 3 | 2009 | 75 | 0.170 |
Why?
| | Prospective Studies | 11 | 2020 | 7604 | 0.170 |
Why?
| | Bupivacaine | 1 | 2000 | 32 | 0.170 |
Why?
| | Reperfusion | 1 | 2020 | 40 | 0.170 |
Why?
| | Educational Status | 3 | 2022 | 470 | 0.170 |
Why?
| | Diagnostic Imaging | 2 | 2013 | 332 | 0.170 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 177 | 0.170 |
Why?
| | Temperature | 1 | 2023 | 679 | 0.170 |
Why?
| | Analgesia, Epidural | 1 | 2000 | 33 | 0.170 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2020 | 9 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2024 | 956 | 0.170 |
Why?
| | Anesthetics, Local | 1 | 2000 | 80 | 0.170 |
Why?
| | Thymidine Phosphorylase | 1 | 2020 | 14 | 0.160 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 46 | 0.160 |
Why?
| | Costs and Cost Analysis | 3 | 2024 | 213 | 0.160 |
Why?
| | Incidence | 6 | 2025 | 2804 | 0.160 |
Why?
| | Cholestasis | 1 | 2023 | 235 | 0.160 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 84 | 0.160 |
Why?
| | Policy | 1 | 2021 | 150 | 0.160 |
Why?
| | Choline | 4 | 1989 | 127 | 0.160 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 289 | 0.160 |
Why?
| | Disease Progression | 5 | 2025 | 2757 | 0.160 |
Why?
| | Nephrectomy | 1 | 2020 | 169 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2012 | 3284 | 0.150 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 307 | 0.150 |
Why?
| | Viremia | 1 | 2020 | 138 | 0.150 |
Why?
| | Medicare | 1 | 2024 | 773 | 0.150 |
Why?
| | Biliary Atresia | 1 | 2020 | 163 | 0.150 |
Why?
| | Catheterization | 2 | 2023 | 179 | 0.150 |
Why?
| | Risk | 3 | 2016 | 912 | 0.150 |
Why?
| | Amyloid Neuropathies | 1 | 1998 | 1 | 0.150 |
Why?
| | Gastric Bypass | 1 | 2020 | 119 | 0.150 |
Why?
| | Age Distribution | 2 | 2011 | 392 | 0.150 |
Why?
| | Mice, SCID | 3 | 2025 | 367 | 0.150 |
Why?
| | Cohort Studies | 9 | 2025 | 5742 | 0.140 |
Why?
| | Bile Duct Diseases | 1 | 2017 | 14 | 0.140 |
Why?
| | Phlebography | 1 | 2017 | 38 | 0.140 |
Why?
| | Telomerase | 1 | 2020 | 250 | 0.140 |
Why?
| | Premature Birth | 1 | 2021 | 333 | 0.140 |
Why?
| | Prevalence | 3 | 2023 | 2734 | 0.140 |
Why?
| | Obesity, Morbid | 2 | 2020 | 264 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 606 | 0.130 |
Why?
| | Reoperation | 6 | 2017 | 573 | 0.130 |
Why?
| | Drug Overdose | 1 | 2021 | 347 | 0.130 |
Why?
| | Incidental Findings | 1 | 2017 | 87 | 0.130 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 89 | 0.130 |
Why?
| | North America | 3 | 2025 | 313 | 0.130 |
Why?
| | Ultrasonography, Doppler | 1 | 2017 | 124 | 0.130 |
Why?
| | Bariatric Surgery | 1 | 2020 | 217 | 0.130 |
Why?
| | Child | 8 | 2022 | 21935 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2016 | 5778 | 0.130 |
Why?
| | Antibodies, Monoclonal | 3 | 2024 | 1430 | 0.120 |
Why?
| | Social Determinants of Health | 1 | 2020 | 267 | 0.120 |
Why?
| | Perioperative Care | 1 | 2017 | 178 | 0.120 |
Why?
| | Communicable Diseases | 1 | 2017 | 159 | 0.120 |
Why?
| | Postoperative Period | 4 | 2020 | 342 | 0.120 |
Why?
| | Postoperative Care | 1 | 2017 | 261 | 0.120 |
Why?
| | Iron | 1 | 2017 | 313 | 0.120 |
Why?
| | Morbidity | 2 | 2013 | 324 | 0.120 |
Why?
| | Monitoring, Physiologic | 2 | 1994 | 275 | 0.110 |
Why?
| | Mycophenolic Acid | 2 | 2014 | 117 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 872 | 0.110 |
Why?
| | Cadaver | 3 | 2015 | 296 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1477 | 0.110 |
Why?
| | Transplantation | 2 | 2024 | 34 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2023 | 938 | 0.110 |
Why?
| | Parents | 2 | 2020 | 1347 | 0.110 |
Why?
| | Antilymphocyte Serum | 1 | 2014 | 66 | 0.110 |
Why?
| | Organ Size | 2 | 2012 | 477 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 698 | 0.110 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2015 | 91 | 0.110 |
Why?
| | Withholding Treatment | 1 | 2014 | 76 | 0.110 |
Why?
| | Comorbidity | 1 | 2019 | 1622 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 515 | 0.110 |
Why?
| | Choline Deficiency | 3 | 1991 | 11 | 0.110 |
Why?
| | Steroids | 1 | 2014 | 167 | 0.100 |
Why?
| | Splenorenal Shunt, Surgical | 2 | 2006 | 3 | 0.100 |
Why?
| | Mitochondria | 1 | 2020 | 948 | 0.100 |
Why?
| | Immunophenotyping | 1 | 2014 | 318 | 0.100 |
Why?
| | Thoracic Injuries | 1 | 1993 | 55 | 0.100 |
Why?
| | Physician Executives | 1 | 2013 | 31 | 0.100 |
Why?
| | Data Collection | 2 | 2013 | 673 | 0.100 |
Why?
| | Anticoagulants | 1 | 2017 | 664 | 0.100 |
Why?
| | Receptors, CCR4 | 2 | 2024 | 22 | 0.100 |
Why?
| | Cooperative Behavior | 1 | 2015 | 451 | 0.100 |
Why?
| | Catheterization, Central Venous | 1 | 1994 | 112 | 0.100 |
Why?
| | Personnel Selection | 1 | 2013 | 78 | 0.090 |
Why?
| | Therapeutic Equipoise | 1 | 2011 | 2 | 0.090 |
Why?
| | Anesthesiology | 1 | 2013 | 87 | 0.090 |
Why?
| | Liver Function Tests | 2 | 2020 | 114 | 0.090 |
Why?
| | Mental Health | 1 | 2018 | 726 | 0.090 |
Why?
| | Catheter Ablation | 1 | 2015 | 350 | 0.090 |
Why?
| | Mice, Inbred NOD | 2 | 2025 | 601 | 0.090 |
Why?
| | Mice | 6 | 2025 | 17787 | 0.090 |
Why?
| | Anastomosis, Surgical | 1 | 2011 | 153 | 0.090 |
Why?
| | Religion | 1 | 2011 | 71 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 2 | 2011 | 889 | 0.090 |
Why?
| | Family Relations | 1 | 2011 | 91 | 0.090 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3412 | 0.090 |
Why?
| | Health Status Indicators | 1 | 2011 | 171 | 0.090 |
Why?
| | Observer Variation | 1 | 2011 | 343 | 0.090 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2022 | 28 | 0.080 |
Why?
| | Hepatitis, Autoimmune | 4 | 2006 | 20 | 0.080 |
Why?
| | Animals | 14 | 2025 | 36940 | 0.080 |
Why?
| | Wounds, Nonpenetrating | 1 | 1993 | 278 | 0.080 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 25 | 0.080 |
Why?
| | Specialties, Surgical | 1 | 2011 | 75 | 0.080 |
Why?
| | Hypertension, Portal | 1 | 2010 | 64 | 0.080 |
Why?
| | Constriction, Pathologic | 2 | 2023 | 245 | 0.080 |
Why?
| | Obesity | 4 | 2024 | 2992 | 0.080 |
Why?
| | Critical Illness | 1 | 2015 | 811 | 0.080 |
Why?
| | S-Adenosylmethionine | 1 | 1989 | 54 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 849 | 0.080 |
Why?
| | Models, Biological | 2 | 2006 | 1783 | 0.080 |
Why?
| | Mutation | 1 | 2020 | 3958 | 0.080 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2009 | 78 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1266 | 0.080 |
Why?
| | Rats, Inbred Strains | 7 | 1991 | 362 | 0.070 |
Why?
| | Life Expectancy | 1 | 2009 | 69 | 0.070 |
Why?
| | Brain Death | 2 | 2024 | 46 | 0.070 |
Why?
| | Methionine | 1 | 1989 | 160 | 0.070 |
Why?
| | Ventilator Weaning | 1 | 2008 | 36 | 0.070 |
Why?
| | Guidelines as Topic | 1 | 2010 | 275 | 0.070 |
Why?
| | Lithium | 1 | 1988 | 43 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 1994 | 1086 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 565 | 0.070 |
Why?
| | Documentation | 2 | 2024 | 194 | 0.070 |
Why?
| | Rats | 8 | 2024 | 5647 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 665 | 0.070 |
Why?
| | General Surgery | 1 | 2010 | 173 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2011 | 893 | 0.070 |
Why?
| | Hypotension | 1 | 2008 | 122 | 0.070 |
Why?
| | Prealbumin | 1 | 2006 | 30 | 0.070 |
Why?
| | Abdomen | 2 | 2024 | 125 | 0.070 |
Why?
| | Heart Failure | 1 | 2020 | 2236 | 0.060 |
Why?
| | Parenteral Nutrition, Total | 2 | 2003 | 26 | 0.060 |
Why?
| | Survival Analysis | 4 | 2015 | 1325 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 804 | 0.060 |
Why?
| | Demography | 1 | 2007 | 291 | 0.060 |
Why?
| | Safety | 1 | 2008 | 338 | 0.060 |
Why?
| | Esophageal and Gastric Varices | 1 | 2006 | 40 | 0.060 |
Why?
| | Neoplasm Staging | 1 | 2009 | 1389 | 0.060 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2006 | 132 | 0.060 |
Why?
| | Pain | 2 | 2022 | 756 | 0.060 |
Why?
| | Renal Veins | 1 | 2024 | 19 | 0.060 |
Why?
| | Algorithms | 2 | 2011 | 1704 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1313 | 0.050 |
Why?
| | Canada | 1 | 2025 | 418 | 0.050 |
Why?
| | Xanthomatosis | 1 | 2004 | 9 | 0.050 |
Why?
| | Swine, Miniature | 1 | 2024 | 82 | 0.050 |
Why?
| | Employment | 1 | 2005 | 178 | 0.050 |
Why?
| | Salvage Therapy | 1 | 2024 | 142 | 0.050 |
Why?
| | Granuloma | 1 | 2004 | 92 | 0.050 |
Why?
| | Bilirubin | 1 | 2023 | 97 | 0.050 |
Why?
| | Patient Care | 1 | 2004 | 111 | 0.050 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2003 | 18 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 11 | 0.050 |
Why?
| | Depression | 2 | 2018 | 1397 | 0.050 |
Why?
| | Shock | 1 | 2024 | 98 | 0.050 |
Why?
| | Perioperative Period | 1 | 2022 | 56 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 358 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2014 | 1996 | 0.050 |
Why?
| | Laboratories | 1 | 2023 | 113 | 0.050 |
Why?
| | Platelet Count | 1 | 2022 | 86 | 0.050 |
Why?
| | Research | 1 | 2006 | 451 | 0.050 |
Why?
| | Infant | 3 | 2021 | 9465 | 0.050 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2002 | 17 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2022 | 86 | 0.050 |
Why?
| | Information Dissemination | 1 | 2024 | 218 | 0.050 |
Why?
| | Mentors | 1 | 2024 | 202 | 0.050 |
Why?
| | Pain Measurement | 1 | 2024 | 521 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2009 | 1991 | 0.050 |
Why?
| | Propensity Score | 1 | 2023 | 294 | 0.050 |
Why?
| | Platelet Transfusion | 1 | 2022 | 67 | 0.050 |
Why?
| | Patients | 1 | 2023 | 175 | 0.050 |
Why?
| | RNA, Viral | 3 | 2013 | 656 | 0.050 |
Why?
| | Hypophosphatemia | 1 | 2001 | 17 | 0.050 |
Why?
| | Swine | 1 | 2024 | 775 | 0.040 |
Why?
| | Creatinine | 1 | 2023 | 499 | 0.040 |
Why?
| | Family | 1 | 2005 | 671 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 558 | 0.040 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 72 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 59 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2020 | 126 | 0.040 |
Why?
| | Computer Systems | 1 | 2020 | 45 | 0.040 |
Why?
| | Viscosity | 1 | 2020 | 92 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 329 | 0.040 |
Why?
| | Thymidine | 1 | 2020 | 60 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 90 | 0.040 |
Why?
| | Preoperative Care | 1 | 2022 | 362 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2020 | 160 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 81 | 0.040 |
Why?
| | Esophageal Motility Disorders | 1 | 2020 | 27 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 6079 | 0.040 |
Why?
| | Remission Induction | 1 | 2020 | 288 | 0.040 |
Why?
| | HLA-DR Antigens | 1 | 2020 | 228 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2001 | 752 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2022 | 614 | 0.040 |
Why?
| | Hemangioma, Cavernous | 1 | 1999 | 15 | 0.040 |
Why?
| | Sex Distribution | 1 | 2020 | 375 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2023 | 435 | 0.040 |
Why?
| | HLA Antigens | 1 | 2020 | 240 | 0.040 |
Why?
| | Gastrectomy | 1 | 2020 | 126 | 0.040 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2020 | 128 | 0.040 |
Why?
| | Blood Platelets | 1 | 2022 | 408 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1910 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3295 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2021 | 416 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 674 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 317 | 0.040 |
Why?
| | Pilot Projects | 2 | 2014 | 1710 | 0.040 |
Why?
| | Anatomic Variation | 1 | 2017 | 3 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2005 | 2844 | 0.040 |
Why?
| | Hepcidins | 1 | 2017 | 22 | 0.040 |
Why?
| | Nervous System | 1 | 1998 | 67 | 0.040 |
Why?
| | Pancreas Transplantation | 2 | 2009 | 75 | 0.030 |
Why?
| | Mammary Glands, Animal | 2 | 1988 | 129 | 0.030 |
Why?
| | Ferritins | 1 | 2017 | 64 | 0.030 |
Why?
| | Boston | 1 | 2017 | 91 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 530 | 0.030 |
Why?
| | Hepatic Artery | 3 | 2003 | 62 | 0.030 |
Why?
| | Phosphatidylcholines | 2 | 1988 | 147 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1353 | 0.030 |
Why?
| | Cardiovascular System | 1 | 1998 | 137 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1000 | 0.030 |
Why?
| | Communication | 1 | 2022 | 879 | 0.030 |
Why?
| | Sepsis | 1 | 2022 | 617 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 202 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2020 | 1178 | 0.030 |
Why?
| | Acute-On-Chronic Liver Failure | 1 | 2015 | 7 | 0.030 |
Why?
| | Hepatic Encephalopathy | 1 | 2015 | 21 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1357 | 0.030 |
Why?
| | Hepatorenal Syndrome | 1 | 2015 | 16 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 329 | 0.030 |
Why?
| | Cross Infection | 1 | 1998 | 256 | 0.030 |
Why?
| | Contraindications | 2 | 2006 | 90 | 0.030 |
Why?
| | Peritonitis | 1 | 2015 | 84 | 0.030 |
Why?
| | Benchmarking | 1 | 2016 | 186 | 0.030 |
Why?
| | Contrast Media | 2 | 2013 | 467 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 916 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 499 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 951 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2017 | 364 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 147 | 0.030 |
Why?
| | Aged, 80 and over | 4 | 2011 | 7635 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 622 | 0.030 |
Why?
| | Mesothelioma | 2 | 1985 | 44 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 282 | 0.030 |
Why?
| | Genotype | 2 | 2013 | 1916 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2016 | 325 | 0.030 |
Why?
| | Peritoneal Neoplasms | 2 | 1985 | 93 | 0.030 |
Why?
| | Equipment Failure | 1 | 1994 | 108 | 0.030 |
Why?
| | Constitution and Bylaws | 1 | 2013 | 1 | 0.030 |
Why?
| | Decision Trees | 1 | 1993 | 93 | 0.030 |
Why?
| | Hospitals, Low-Volume | 1 | 2013 | 22 | 0.030 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 67 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1639 | 0.030 |
Why?
| | Hospitals, High-Volume | 1 | 2013 | 44 | 0.030 |
Why?
| | Rabbits | 1 | 2014 | 794 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 1991 | 597 | 0.020 |
Why?
| | Pediatrics | 1 | 2001 | 1101 | 0.020 |
Why?
| | Viral Envelope Proteins | 1 | 2013 | 84 | 0.020 |
Why?
| | Certification | 1 | 2013 | 113 | 0.020 |
Why?
| | Clinical Protocols | 1 | 1993 | 271 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1509 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 591 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 565 | 0.020 |
Why?
| | Alcoholism | 1 | 2018 | 807 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 548 | 0.020 |
Why?
| | Patient Readmission | 1 | 2016 | 697 | 0.020 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 1993 | 249 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 1035 | 0.020 |
Why?
| | Education | 1 | 2011 | 108 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 1993 | 810 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 1062 | 0.020 |
Why?
| | Biological Transport | 2 | 1988 | 418 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2057 | 0.020 |
Why?
| | Pregnancy | 2 | 2021 | 6763 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1993 | 318 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 1139 | 0.020 |
Why?
| | Folic Acid | 1 | 1991 | 186 | 0.020 |
Why?
| | Methotrexate | 1 | 1991 | 260 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2004 | 1483 | 0.020 |
Why?
| | Cholagogues and Choleretics | 1 | 2009 | 8 | 0.020 |
Why?
| | Ursodeoxycholic Acid | 1 | 2009 | 21 | 0.020 |
Why?
| | Ethics, Medical | 1 | 2010 | 84 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 1998 | 1040 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 1989 | 132 | 0.020 |
Why?
| | Workload | 1 | 2011 | 167 | 0.020 |
Why?
| | Leadership | 1 | 2013 | 388 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1066 | 0.020 |
Why?
| | Phosphatidylethanolamines | 1 | 1988 | 77 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 556 | 0.020 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 486 | 0.020 |
Why?
| | Life Style | 1 | 2011 | 490 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 240 | 0.020 |
Why?
| | Methyltransferases | 1 | 1988 | 78 | 0.020 |
Why?
| | Gastroenterology | 1 | 2010 | 180 | 0.020 |
Why?
| | Health Policy | 1 | 2011 | 388 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1993 | 0.020 |
Why?
| | Breast | 1 | 1988 | 151 | 0.020 |
Why?
| | Blood Glucose | 1 | 1998 | 2186 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3566 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2011 | 512 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2011 | 578 | 0.020 |
Why?
| | Betaine | 1 | 1988 | 73 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 815 | 0.020 |
Why?
| | Selenium Compounds | 1 | 1987 | 21 | 0.020 |
Why?
| | Selenium | 1 | 1987 | 43 | 0.020 |
Why?
| | Needs Assessment | 1 | 2010 | 376 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 11074 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 1987 | 111 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4149 | 0.020 |
Why?
| | Fellowships and Scholarships | 1 | 2010 | 306 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2008 | 257 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 496 | 0.010 |
Why?
| | Survivors | 1 | 2009 | 493 | 0.010 |
Why?
| | Clinical Competence | 1 | 2013 | 1118 | 0.010 |
Why?
| | Podophyllotoxin | 1 | 1984 | 7 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5472 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 158 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1984 | 172 | 0.010 |
Why?
| | Tissue Adhesions | 1 | 2004 | 32 | 0.010 |
Why?
| | Lacerations | 1 | 2004 | 35 | 0.010 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2004 | 93 | 0.010 |
Why?
| | Curriculum | 1 | 2010 | 992 | 0.010 |
Why?
| | Internship and Residency | 1 | 2013 | 1147 | 0.010 |
Why?
| | Intraoperative Complications | 1 | 2004 | 138 | 0.010 |
Why?
| | Angiography | 1 | 2003 | 207 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 1988 | 623 | 0.010 |
Why?
| | Hepatitis C Antibodies | 1 | 2002 | 11 | 0.010 |
Why?
| | Inflammation | 1 | 1993 | 2837 | 0.010 |
Why?
| | Erythrocytes | 1 | 1988 | 700 | 0.010 |
Why?
| | Azathioprine | 1 | 2001 | 54 | 0.010 |
Why?
| | Blood Pressure | 1 | 2008 | 1786 | 0.010 |
Why?
| | Spleen | 1 | 2003 | 514 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2001 | 233 | 0.010 |
Why?
| | Ischemia | 1 | 2003 | 409 | 0.010 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2003 | 351 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2003 | 460 | 0.010 |
Why?
| | APACHE | 1 | 1998 | 69 | 0.010 |
Why?
| | Imaging, Three-Dimensional | 1 | 2001 | 580 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1998 | 227 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1999 | 259 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1946 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1983 | 1692 | 0.010 |
Why?
| | Combined Modality Therapy | 2 | 1985 | 1236 | 0.010 |
Why?
| | Pteroylpolyglutamic Acids | 1 | 1991 | 1 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1984 | 2526 | 0.010 |
Why?
| | Tetrahydrofolates | 1 | 1991 | 18 | 0.010 |
Why?
| | Phosphatidylethanolamine N-Methyltransferase | 1 | 1988 | 8 | 0.000 |
Why?
| | Hemicholinium 3 | 1 | 1988 | 1 | 0.000 |
Why?
| | Dinitrophenols | 1 | 1988 | 8 | 0.000 |
Why?
| | 2,4-Dinitrophenol | 1 | 1988 | 9 | 0.000 |
Why?
| | Ouabain | 1 | 1988 | 16 | 0.000 |
Why?
| | Osmolar Concentration | 1 | 1988 | 171 | 0.000 |
Why?
| | Methylation | 1 | 1988 | 230 | 0.000 |
Why?
| | Selenium Radioisotopes | 1 | 1987 | 2 | 0.000 |
Why?
| | Selenious Acid | 1 | 1987 | 3 | 0.000 |
Why?
| | Selenomethionine | 1 | 1987 | 4 | 0.000 |
Why?
| | Milk | 1 | 1988 | 124 | 0.000 |
Why?
| | Lactation | 1 | 1988 | 181 | 0.000 |
Why?
| | Epithelium | 1 | 1988 | 313 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1988 | 1092 | 0.000 |
Why?
| | Drug Evaluation | 1 | 1984 | 84 | 0.000 |
Why?
| | Kinetics | 1 | 1988 | 1670 | 0.000 |
Why?
| | Asbestos | 1 | 1983 | 38 | 0.000 |
Why?
| | Laparotomy | 1 | 1983 | 109 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1988 | 1096 | 0.000 |
Why?
| | Palliative Care | 1 | 1985 | 758 | 0.000 |
Why?
|
|
Pomfret's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|